COPD

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

The Prescription Drug User Fee Act date is set for May 7, 2025.

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Your daily dose of the clinical news you may have missed.

CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.

CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.

The combined bronchodilator/anti-inflammatory agent significantly improved lung function, symptoms and QoL in adults with moderate or severe airflow obstruction.